The Effect of Folinic Acid on Methylenetetrahydrofolate Reductase Polymorphisms in Methotrexate-Treated Allogeneic Hematopoietic Stem Cell Transplants

Nicholas M. Murphy(Genetic Technologies (Australia)), Brian D. Tait(Australian Red Cross Lifeblood), Mary Diviney(Australian Red Cross Lifeblood), Rhonda Holdsworth(Australian Red Cross Lifeblood), Andrew Grigg(The Royal Melbourne Hospital), Belinda King-Kallimanis(University of Amsterdam), Peter Bardy(Royal Adelaide Hospital), James McCluskey(Peter Doherty Institute), R Hoyt(The Royal Melbourne Hospital), Jeff Szer(The Royal Melbourne Hospital)
Transplantation and Cellular Therapy
September 16, 2011
10.1016/j.bbmt.2011.09.001
Cited by 11

Related Papers

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859
Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation
|Transplantation|2012|777
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
|Blood|2013|705
Immune self-reactivity triggered by drug-modified HLA-peptide repertoire
|Nature|2012|695